Aprea Therapeutics Inc APRE

2d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating

6d ago, source:

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) and keeping the price ...

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

on MSN ago, source:

Monday, Aprea Therapeutics Inc (NASDAQ:APRE) announced that the FDA has cleared its Investigational New Drug (IND) ...

Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline

1mon ago, source: Business Insider

Aprea Therapeutics (APRE) Company Description: Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that ...

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

1mon ago, source: Nasdaq

DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical ...

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

1mon ago, source: KRQE Blogs

$16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total ...

Aprea Therapeutics CFO buys $7,362 in company stock

1mon ago, source: Investing

Hamill, the Senior Vice President, Chief Financial Officer, and Principal Financial (NASDAQ:PFG) and Accounting Officer of Aprea Therapeutics, Inc. (NASDAQ:APRE), has increased his stake in the ...

Aprea Therapeutics, Inc. (APRE)

2d ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Aprea Therapeutics Inc APRE

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aprea Therapeutics Inc (APRE)

27d ago, source: Investing

In a recent transaction on March 13, John B. Henneman III, a director of Aprea Therapeutics, Inc. (NASDAQ:APRE), purchased 6,860 shares of the company's common stock. The... Aprea Therapeutics ...